Earnings summaries and quarterly performance for Kiniksa Pharmaceuticals International.
Executive leadership at Kiniksa Pharmaceuticals International.
Sanj K. Patel
Detailed
Chief Executive Officer
CEO
ET
Eben Tessari
Detailed
Executive Vice President and Chief Operating Officer
JF
John F. Paolini
Detailed
Executive Vice President and Chief Medical Officer
MR
Mark Ragosa
Detailed
Senior Vice President and Chief Financial Officer
MM
Michael Megna
Detailed
Chief Accounting Officer
RM
Ross Moat
Detailed
Executive Vice President and Chief Commercial Officer
Board of directors at Kiniksa Pharmaceuticals International.
BD
Barry D. Quart
Detailed
Director
FJ
Felix J. Baker
Detailed
Lead Independent Director
GB
G. Bradley Cole
Detailed
Director
KJ
Kimberly J. Popovits
Detailed
Director
MC
M. Cantey Boyd
Detailed
Director
RS
Richard S. Levy
Detailed
Director
SR
Stephen R. Biggar
Detailed
Director
TR
Thomas R. Malley
Detailed
Director
TL
Tracey L. McCain
Detailed
Director
Research analysts who have asked questions during Kiniksa Pharmaceuticals International earnings calls.
AR
Anupam Rama
JPMorgan Chase & Co.
5 questions for KNSA
Also covers: APLS, BBIO, BOLD +18 more
Eva Fortea-Verdejo
Wells Fargo Securities
5 questions for KNSA
Also covers: EXEL, KYMR, RCUS
David Nierengarten
Wedbush Securities
4 questions for KNSA
Also covers: ARGX, ITOS, NUVB +4 more
RS
Roger Song
Jefferies
4 questions for KNSA
Also covers: AADI, AKBA, ALT +14 more
Geoff Meacham
Citigroup Inc.
3 questions for KNSA
Also covers: ABBV, AMGN, BMY +11 more
PC
Paul Choi
Goldman Sachs
3 questions for KNSA
Also covers: AMRN, ARVN, ASND +13 more
EF
Eva Fortea
Wells Fargo
2 questions for KNSA
Also covers: IMCR
JS
Jiale Song
Jefferies Financial Group Inc.
2 questions for KNSA
Also covers: ACRS, CRVS, CTMX +12 more
NL
Nick Lorusso
TD Cowen
2 questions for KNSA
Also covers: DAWN, IOVA, TLX
JC
Joyce Chang
JPMorgan Chase & Co.
1 question for KNSA
JZ
Joysree Zanfir
JPMorgan Chase & Co.
1 question for KNSA
KC
Kyuwon Choi
Goldman Sachs
1 question for KNSA
Also covers: AMRN, ASND, BHVN +9 more
Liisa Bayko
Evercore ISI
1 question for KNSA
Also covers: ALT, BCRX, INSM +7 more
MK
Mary Kate
Citigroup Inc.
1 question for KNSA
NL
Nick Larissa
TD Cowen
1 question for KNSA
Recent press releases and 8-K filings for KNSA.
Kiniksa Pharmaceuticals International announces Q4 and Full Year 2025 Financial Results
KNSA
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Kiniksa Pharmaceuticals International reported ARCALYST revenue of $202.1 million for Q4 2025 and $677.6 million for the full year 2025, representing approximately 62% year-over-year growth.
- The company achieved a net income of $59.0 million for the full year 2025.
- Kiniksa provided 2026 ARCALYST revenue guidance of $900-920 million.
- The company ended 2025 with a strong financial position, holding $414.1 million in cash, cash equivalents, and short-term investments as of December 31, 2025, and anticipates remaining cash flow positive on an annual basis.
- Key pipeline advancements include Phase 2 data for KPL-387 expected in 2H 2026 and the KPL-1161 Phase 1 trial initiating by the end of 2026.
4 days ago
Kiniksa Pharmaceuticals International Reports Strong Q4 and Full Year 2025 Results, Provides 2026 Arcalyst Guidance
KNSA
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Kiniksa Pharmaceuticals International reported Arcalyst product revenue of $202.1 million in Q4 2025, a 65% year-over-year increase, and $677.6 million for the full year 2025, a 62% increase. The company achieved a net income of $14.2 million in Q4 2025 and $59 million for the full year 2025, ending the year with $414.1 million in cash.
- For full year 2026, Kiniksa expects Arcalyst net revenue to be between $900 million and $920 million.
- Arcalyst's penetration into the 2-plus recurrence target market reached approximately 18% by the end of 2025, an increase from 13% at the end of 2024.
- The company is advancing its pipeline, with KPL-387 in a Phase 2/3 clinical trial and Phase 2 data expected in the second half of 2026, and plans to initiate clinical trials for KPL-1161 by the end of 2026.
4 days ago
Kiniksa Reports Strong Q4 and Full Year 2025 Financial Results, Provides 2026 Revenue Guidance
KNSA
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Kiniksa reported Arcalyst product revenue of $202.1 million for Q4 2025, a 65% year-over-year increase, and $677.6 million for the full year 2025, representing 62% year-over-year growth. The company achieved a net income of $14.2 million in Q4 2025 and $59 million for the full year 2025, a significant improvement from net losses in the prior year.
- For the full year 2026, Kiniksa reiterates its net revenue guidance for Arcalyst to be between $900 million and $920 million.
- Arcalyst's penetration into the 2-plus recurrence target market reached approximately 18% by the end of 2025, up from 13% at the end of 2024. Over 4,150 prescribers have written a prescription for Arcalyst, with more than 1,200 having written for two or more patients.
- The company is advancing its pipeline, with data from the Phase 2 portion of the KPL-387 clinical trial expected in the second half of 2026, aiming for a launch in the 2028-2029 timeframe. Additionally, KPL-1161 is planned to enter the clinic by the end of 2026.
4 days ago
Kiniksa Pharmaceuticals International Reports Strong Q4 and Full-Year 2025 Financial Results
KNSA
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Kiniksa Pharmaceuticals International reported ARCALYST product revenue of $202.1 million in Q4 2025, representing a 65% year-over-year increase, and $677.6 million for the full year 2025, up 62% from the previous year.
- The company achieved net income of $14.2 million in Q4 2025 and $59 million for the full year 2025, a significant improvement from net losses in the prior year.
- Kiniksa ended 2025 with $414.1 million in cash, having generated $170.4 million in net cash during the year, and expects to remain cash flow positive on an annual basis under its current operating plan.
- The company reiterated its full-year 2026 net revenue guidance for ARCALYST of between $900 million and $920 million.
- ARCALYST's market penetration into the two-plus recurrence target market increased to approximately 18% by the end of 2025, and the pipeline asset KPL-387 is on track for Phase II data in the second half of 2026.
4 days ago
Kiniksa Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results and 2026 Guidance
KNSA
Earnings
Guidance Update
New Projects/Investments
- ARCALYST net product revenue was $202.1 million for the fourth quarter of 2025 and $677.6 million for the full year 2025.
- Kiniksa expects ARCALYST net product revenue for 2026 to be between $900 million and $920 million.
- For the full year 2025, the company reported total revenue of $677.6 million and net income of $59.0 million.
- As of December 31, 2025, Kiniksa held $414.1 million in cash, cash equivalents, and short-term investments, with no debt.
- Kiniksa anticipates KPL-387 Phase 2 recurrent pericarditis data in the second half of 2026 and plans to initiate a KPL-1161 Phase 1 trial by the end of 2026.
4 days ago
Kiniksa Pharmaceuticals Provides Corporate Update and 2026 ARCALYST Revenue Guidance
KNSA
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Kiniksa Pharmaceuticals reported unaudited ARCALYST net product revenue of $677.5 million for the full year 2025, marking approximately 62% year-over-year growth from $417.0 million in 2024.
- The company projects 2026 ARCALYST net product revenue to be between $900 million and $920 million.
- As of December 31, 2025, Kiniksa held an unaudited cash, cash equivalents, and short-term investments balance of $414.1 million, with no debt.
- Kiniksa expects KPL-387 Phase 2 recurrent pericarditis data in the second half of 2026 and plans to initiate a KPL-1161 Phase 1 trial by the end of 2026.
Jan 12, 2026, 10:22 PM
Kiniksa Reports Strong ARCALYST Revenue and Provides 2026 Guidance
KNSA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Kiniksa reported full year 2025 unaudited net revenue of $677.5 million for ARCALYST, representing 62% year-over-year growth, and issued 2026 net product revenue guidance of $900-$920 million.
- ARCALYST has generated around $1.5 billion in cumulative net revenue since its launch and is being positioned as the second-line standard of care for recurrent pericarditis, supported by new ACC clinical guidance.
- The company is advancing KPL-387 in a Phase 2/3 study for recurrent pericarditis, with dose-focusing data expected in the second half of 2026 and a commercialization target of 2028-2029.
- Kiniksa also plans for KPL-1161 to enter the clinic by the end of 2026 and reported around $414 million in year-end cash reserves.
Jan 12, 2026, 10:15 PM
Kiniksa Updates on ARCALYST Performance and Pipeline Progress
KNSA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Kiniksa reported full year 2025 unaudited net revenue of $677.5 million for ARCALYST, representing 62% year-over-year growth, and provided 2026 net product revenue guidance of $900-$920 million.
- The company is advancing its clinical portfolio, with KPL-387 in a phase 2/3 study for recurrent pericarditis, expecting dose-focusing data in the second half of 2026, and KPL-1161 anticipated to enter the clinic by the end of 2026.
- Commercialization efforts for ARCALYST are focused on establishing it as the second-line standard of care for recurrent pericarditis, with 18% penetration into the multiple recurrent patient group by the end of 2025, up from 13% at the end of 2024.
- Kiniksa ended the year with approximately $414 million in cash reserves and saw 325 additional new ARCALYST prescribers in Q4 2025, bringing the total to over 4,150 prescribers.
Jan 12, 2026, 10:15 PM
Kiniksa Reports Strong 2025 ARCALYST Revenue and Provides 2026 Guidance
KNSA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Kiniksa announced full year 2025 unaudited net revenue for ARCALYST of $677.5 million, representing 62% year-over-year growth, and issued full year 2026 net product revenue guidance of $900-$920 million.
- ARCALYST has generated approximately $1.5 billion in cumulative net revenue since its launch, and Kiniksa ended 2025 with around $414 million in cash reserves.
- The company is advancing its pipeline, with KPL-387 in a Phase 2/3 study for recurrent pericarditis, expecting data from the dose-focusing portion in the second half of 2026 and targeting commercialization in 2028-2029.
- Kiniksa also plans for KPL-1161, an Fc-modified IL-1 alpha and beta inhibitor, to enter the clinic by the end of 2026.
Jan 12, 2026, 10:15 PM
Kiniksa Reports Strong ARCALYST Performance and Advances Clinical Pipeline
KNSA
Guidance Update
New Projects/Investments
Earnings
- Kiniksa (KNSA) projects ARCALYST revenue of $900M to $920M for 2026 and reported $180.9M in product revenue for Q3 2025, contributing to $18.4M in net income for the quarter.
- The company maintained a strong financial position with approximately $414M in cash reserves at the end of 2025 and anticipates remaining cash flow positive on an annual basis.
- ARCALYST has achieved ~$1.5B in net revenue since launch and has become the ACC-recommended second-line treatment for recurrent pericarditis, with its use increasing to 71% in 2023.
- Kiniksa is advancing its clinical pipeline, with KPL-387 in a Phase 2/3 trial for recurrent pericarditis, expecting Phase 2 data in 2H 2026, and KPL-1161 initiating a Phase 1 trial by the end of 2026.
Jan 12, 2026, 12:00 PM
Quarterly earnings call transcripts for Kiniksa Pharmaceuticals International.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more